PMID- 20637879
OWN - NLM
STAT- MEDLINE
DCOM- 20110128
LR  - 20181201
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 16
IP  - 10
DP  - 2010 Oct
TI  - NCI first international workshop on the biology, prevention, and treatment of 
      relapse after allogeneic hematopoietic stem cell transplantation: report from the 
      committee on disease-specific methods and strategies for monitoring relapse 
      following allogeneic stem cell transplantation. part II: chronic leukemias, 
      myeloproliferative neoplasms, and lymphoid malignancies.
PG  - 1325-46
LID - 10.1016/j.bbmt.2010.07.001 [doi]
AB  - Relapse has become the major cause of treatment failure after allogeneic 
      hematopoietic stem cell transplantation. Outcome of patients with clinical 
      relapse after transplantation generally remains poor, but intervention prior to 
      florid relapse improves outcome for certain hematologic malignancies. To detect 
      early relapse or minimal residual disease, sensitive methods such as molecular 
      genetics, tumor-specific molecular primers, fluorescence in situ hybridization 
      (FISH), and multiparameter flow cytometry (MFC) are commonly used after 
      allogeneic stem cell transplantation to monitor patients, but not all of them are 
      included in the commonly employed disease-specific response criteria. The highest 
      sensitivity and specificity can be achieved by molecular monitoring of tumor- or 
      patient-specific markers measured by polymerase chain reaction-based techniques, 
      but not all diseases have such targets for monitoring. Similar high sensitivity 
      can be achieved by determination of recipient-donor chimerism, but its 
      specificity regarding detection of relapse is low and differs substantially among 
      diseases. Here, we summarize the current knowledge about the utilization of such 
      sensitive monitoring techniques in chronic leukemias, myeloproliferative 
      neoplasms, and lymphoid malignancies based on tumor-specific markers and cell 
      chimerism and how these methods might augment the standard definitions of 
      posttransplant remission, persistence, progression, relapse, and the prediction 
      of relapse. Critically important is the need for standardization of the different 
      residual disease techniques and to assess the clinical relevance of minimal 
      residual disease and chimerism surveillance in individual diseases, which in turn 
      must be followed by studies to assess the potential impact of specific 
      interventional strategies.
CI  - Copyright (c) 2010 American Society for Blood and Marrow Transplantation. All 
      rights reserved.
FAU - Kroger, Nicolaus
AU  - Kroger N
AD  - Department for Stem Cell Transplantation, University Medical Center 
      Hamburg-Eppendorf, Germany. nkroeger@uke.uni-hamburg.du
FAU - Bacher, Ulrike
AU  - Bacher U
FAU - Bader, Peter
AU  - Bader P
FAU - Bottcher, Sebastian
AU  - Bottcher S
FAU - Borowitz, Michael J
AU  - Borowitz MJ
FAU - Dreger, Peter
AU  - Dreger P
FAU - Khouri, Issa
AU  - Khouri I
FAU - Olavarria, Eduardo
AU  - Olavarria E
FAU - Radich, Jerald
AU  - Radich J
FAU - Stock, Wendy
AU  - Stock W
FAU - Vose, Julie M
AU  - Vose JM
FAU - Weisdorf, Daniel
AU  - Weisdorf D
FAU - Willasch, Andre
AU  - Willasch A
FAU - Giralt, Sergio
AU  - Giralt S
FAU - Bishop, Michael R
AU  - Bishop MR
FAU - Wayne, Alan S
AU  - Wayne AS
LA  - eng
PT  - Congress
DEP - 20100715
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - Diagnostic Imaging/methods
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia/diagnosis/drug therapy/prevention & control/*surgery
MH  - Lymphoma/diagnosis/drug therapy/prevention & control/*surgery
MH  - Molecular Diagnostic Techniques
MH  - Myeloproliferative Disorders/diagnosis/drug therapy/prevention & control/*surgery
MH  - Neoplasm, Residual
MH  - Predictive Value of Tests
MH  - Secondary Prevention
MH  - Transplantation, Homologous
EDAT- 2010/07/20 06:00
MHDA- 2011/02/01 06:00
CRDT- 2010/07/20 06:00
PHST- 2010/07/03 00:00 [received]
PHST- 2010/07/06 00:00 [accepted]
PHST- 2010/07/20 06:00 [entrez]
PHST- 2010/07/20 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
AID - S1083-8791(10)00291-0 [pii]
AID - 10.1016/j.bbmt.2010.07.001 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2010 Oct;16(10):1325-46. doi: 
      10.1016/j.bbmt.2010.07.001. Epub 2010 Jul 15.